C. Rose

H. Mouridsen, C. Rose, K. Andersen, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

352 An open, comparative randomized trial comparing formestane vs oral megestrol acetate as a second-line therapy in postmenopausal advanced breast cancer patients

C. Boni, F. Jänicke, C. Rose, 1995 .

Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment

K. Jirström, C. Ingvar, C. Rose, 2018, Front. Endocrinol..

Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer.

O. Chinot, I. Christensen, I. Balslev, 1995, International journal of cancer.

Prognostic factors in primary mucinous breast carcinoma.

B. Rasmussen, C. Rose, I. Christensen, 1987, American journal of clinical pathology.

Proper sequence of endocrine therapies in advanced breast cancer.

C. Rose, 1996, Acta oncologica.

Anxiety and depression in cancer patients' spouses

C. Rose, A. Jensen, S. Glasdam, 1996 .

Systemic therapy of metastatic breast cancer.

C. Rose, 1990, Acta oncologica.

Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer.

H. Mouridsen, C. Rose, T. Palshof, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

A Phase III Trial of Zoladex and Flutamide Versus Orchiectomy in the Treatment of Patients With Advanced Carcinoma of the Prostate

C. Rose, P. Klarskov, P. Iversen, 1990, Cancer.

LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study.

R. I. Hansen, C. Rose, P. Iversen, 1989, Scandinavian journal of urology and nephrology.

Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women.

H. Mouridsen, C. Rose, T. Palshof, 1979, Cancer treatment reports.

Treatment of Advanced Breast Cancer with Progestins: A review

H. Mouridsen, C. Rose, M. Salimtschik, 1981, Acta obstetricia et gynecologica Scandinavica. Supplement.

Combination of docetaxel and gemcitabine in the treatment of advanced non-small cell lung cancer (NSCLC)

C. Rose, O. Hansen, N. V. Jensen, 1999 .

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.

R. Thomas, G. Manikhas, C. Rose, 2003, European journal of cancer.

Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature.

C. Rose, O. Hansen, P. Pfeiffer, 1990, European journal of cancer.

Acute non‐lymphocytic leukemia in patients with ovarian carcinoma following long‐term treatment with treosulfan (=dihydroxybusulfan)

N. Nissen, C. Rose, J. Pedersen‐Bjergaard, 1980, Cancer.

Endocrine treatment with anti-estrogen, anti-androgen or progestagen of advanced malignant melanoma: three consecutive phase II trials.

H. Mouridsen, C. Rose, L. Pedersen, 1985, European journal of cancer & clinical oncology.

Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer.

B. Rasmussen, C. Rose, K. Andersen, 1986, Cancer research.

Clinical and electrodiagnostic findings in breast cancer patients with radiation‐induced brachial plexus neuropathy

N. K. Olsen, C. Rose, P. Pfeiffer, 1990, Acta neurologica Scandinavica.

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

Mårten Fernö, Helena Jernström, Christian Ingvar, 2015, EMBO molecular medicine.

Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.

C. Rose, K. Andersen, P. Pfeiffer, 1996, British Journal of Cancer.

Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies

Christian Ingvar, Lisa Rydén, N. Loman, 2011, BMC Cancer.

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

C. Ingvar, C. Rose, P. Jönsson, 2009, British Journal of Cancer.

Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer

C. Ingvar, C. Rose, L. Zeng, 2015, Clinical Cancer Research.

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial

B. Rasmussen, H. Mouridsen, J. Overgaard, 1999, The Lancet.

Flow cytometric DNA ploidy defines patients with poor prognosis in node‐negative breast cancer

I. Christensen, P. Briand, I. Balslev, 2007, International Journal of Cancer.

Spontaneous regrowth of regressed hormone-dependent tumours after long periods of time.

P. Briand, C. Rose, S. Thorpe, 1982, European journal of cancer & clinical oncology.

Hormone-dependent uterine sarcomas in GR mice.

P. Briand, C. Rose, K. Hou‐Jensen, 1981, European journal of cancer.

Histopathological characteristics and oestrogen receptor content in primary breast carcinoma

B. Rasmussen, C. Rose, K. Hou‐Jensen, 2004, Virchows Archiv A.

WEEKLY ORAL IDARUBICIN IN ADVANCED PROSTATIC CANCER

L. Bastholt, C. Rose, K. Bertelsen, 1992 .

Weekly oral idarubicin in advanced prostatic cancer. A phase II study.

L. Bastholt, C. Rose, K. Bertelsen, 1992, Acta oncologica.

Reversible inhibitory activity of sera from breast cancer patients on oestrogen: Effect on cell proliferation and protein synthesis of the human breast cancer cell line MCF-7

P. Briand, C. Rose, A. Lykkesfeldt, 1988 .

Oestrogen reversible inhibitory activity of sera from breast cancer patients [corrected].

P. Briand, C. Rose, A. Lykkesfeldt, 1988, European journal of cancer & clinical oncology.

Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group.

H. Mouridsen, C. Rose, K. Andersen, 1992, Journal of the National Cancer Institute. Monographs.

Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients

K. Jirström, C. Ingvar, C. Rose, 2018, Front. Oncol..

Elastosis in relation to prognosis in primary breast carcinoma.

B. V. Pedersen, B. Rasmussen, C. Rose, 1985, Cancer research.

Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden

C. Ingvar, C. Rose, P. Jönsson, 2011, Acta oncologica.

Integrating cancer patients' perspectives into treatment decisions and treatment evaluation using patient-reported outcomes--a concept paper.

A. Bottomley, J. Huebner, C. Rose, 2014, European journal of cancer care.

Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.

I. Christensen, B. Rasmussen, C. Rose, 1989, Cancer research.

BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES

B. Rasmussen, H. Mouridsen, C. Rose, 1985, The Lancet.

DNA ploidy and S-phase fraction in primary breast carcinomas in relation to prognostic factors and survival for premenopausal patients at high risk for recurrent disease.

I. Christensen, I. Balslev, B. Rasmussen, 1988, Acta oncologica.

The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients.

W Vach, W. Vach, F. B. Sørensen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status

H. Mouridsen, C. Rose, K. Andersen, 1985, World Journal of Surgery.

Biological and clinical relevance of Kd values for estradiol binding in primary breast cancer tumors.

C. Rose, S. Thorpe, 1988, European journal of cancer & clinical oncology.

Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C.

B. Rasmussen, H. Mouridsen, P. Dombernowsky, 1988, Acta oncologica.

Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients

F. B. Sørensen, S. Hansen, A. Laenkholm, 2003, British Journal of Cancer.

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

A. Laenkholm, J. Overgaard, C. Rose, 1998, British Journal of Cancer.

Argyrophilic cells in 202 human mucinous breast carcinomas. Relation to histopathologic and clinical factors.

B. Rasmussen, C. Rose, K. Hou‐Jensen, 1985, American journal of clinical pathology.

Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density.

F. B. Sørensen, C. Rose, M. Bak, 1998, Laboratory investigation; a journal of technical methods and pathology.

Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.

B. Rasmussen, C. Rose, S. Bentzen, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen.

R. Sylvester, H. Mouridsen, C. Rose, 1985, Journal of steroid biochemistry.

Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen.

R. Sylvester, H. Mouridsen, C. Rose, 1985, European journal of cancer & clinical oncology.

Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial.

H. Johansen, C. Rose, M. Overgaard, 1990, International journal of radiation oncology, biology, physics.

CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients

C. Ingvar, C. Rose, Srinivas Veerla, 2016, BMC Cancer.

Fine needle aspiration and Tru-Cut biopsy in the diagnosis of soft tissue metastases in breast cancer.

C. Rose, L. Pedersen, C. Kamby, 1986, European journal of cancer & clinical oncology.

Adjuvant systemic treatment and the pattern of recurrences in patients with breast cancer.

K. Zedeler, C. Rose, K. Andersen, 1988, European journal of cancer & clinical oncology.

Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.

H. Mouridsen, M. Andersson, P. Dombernowsky, 1999, European journal of cancer.

The responsiveness of a tumour to any kind of therapy is reflected by the objective response rate.

C. Rose, 2004, European journal of cancer.

Radiation-induced brachial plexopathy: neurological follow-up in 161 recurrence-free breast cancer patients.

N. K. Olsen, C. Rose, P. Pfeiffer, 1993, International journal of radiation oncology, biology, physics.

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

O. S. Nielsen, L. Bastholt, H. Mouridsen, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients

R. Bouabdallah, C. Rose, P. Fenaux, 1999, Leukemia.

Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients

C. Ingvar, C. Rose, M. Simonsson, 2014, International journal of cancer.

Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort

C. Ingvar, C. Rose, A. Ringberg, 2012, Cancer Causes & Control.

Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG

H. Mouridsen, M. Andersson, P. Dombernowsky, 1999, European journal of cancer.

Vascular grading of angiogenesis: prognostic significance in breast cancer

W Vach, W. Vach, F. B. Sørensen, 2000, British Journal of Cancer.

Caffeine and caffeic acid inhibit growth and modify estrogen receptor ( ER ) and insulin-like growth factor I receptor ( IGF-IR ) levels in human breast cancer

C. Ingvar, C. Rose, L. Zeng, 2014 .

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial

N. Loman, M. Uhlén, K. Jirström, 2013, Breast Cancer Research and Treatment.

Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer

K. Jirström, C. Ingvar, C. Rose, 2017, Front. Endocrinol..

Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups

K. Jirström, C. Ingvar, C. Rose, 2016, Oncotarget.

Oestrogen and progesterone receptor determinations in breast cancer: technology and biology.

C. Rose, S. Thorpe, Thorpe Sm, 1986, Cancer surveys.

Prognostic value of surface antigens in primary human breast carcinomas, detected by monoclonal antibodies.

B. V. Pedersen, C. Rose, S. Thorpe, 1985, Cancer research.

The influence of chemotherapy on survival after recurrence in breast cancer--a population-based study of patients treated in the 1950s, 1960s and 1970s.

C. Rose, S. Cold, H. Brincker, 1993, European journal of cancer.

Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.

H. Mouridsen, P. Dombernowsky, C. Rose, 1988, Acta oncologica.

Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.

H. Mouridsen, P. Dombernowsky, C. Rose, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months.

H. Mouridsen, C. Rose, M. Overgaard, 1993, European journal of cancer.

Coffee Consumption and CYP1A2*1F Genotype Modify Age at Breast Cancer Diagnosis and Estrogen Receptor Status

C. Ingvar, C. Rose, H. Jernström, 2008, Cancer Epidemiology Biomarkers & Prevention.

Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis

C. Ingvar, K. Isaksson, C. Rose, 2018, Cancer Causes & Control.

The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays.

I. Christensen, B. Rasmussen, C. Rose, 1990, European journal of cancer.

Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action.

K. Zedeler, C. Rose, J. Andersen, 1988, British Journal of Cancer.

Identification of plasma protein profiles associated with risk groups of prostate cancer patients

H. Lilja, C. Rose, A. Bjartell, 2014, Proteomics. Clinical applications.

Pattern of spread and progression in relation to the characteristics of the primary tumour in human breast cancer.

K. Zedeler, C. Rose, J. Andersen, 1991, Acta oncologica.

Immunohistochemical assessment of oestrogen and progesterone receptors: correlations with the DCC method and clinical outcome in primary breast cancer patients.

W. Vach, C. Rose, S. Thorpe, 2000, Breast.

The prognostic impact of COX‐2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size

K. Jirström, C. Ingvar, C. Rose, 2017, International journal of cancer.

[Chemotherapy in basal cell carcinoma. Complete remission of locally advanced basal cell carcinoma following treatment with chemotherapy containing cis-platinum].

C. Rose, O. Hansen, P. Pfeiffer, 1989, Ugeskrift for læger.

Of cup and bra size: Reply to a prospective study of breast size and premenopausal breast cancer incidence

Helena Jernström, Christian Ingvar, C. Ingvar, 2006, International journal of cancer.

A woman's build and the risk of breast cancer.

K. Overvad, S. Hansen, C. Rose, 1998, European journal of cancer.

Re: five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

C. Rose, O. Hansen, S. Bentzen, 1997, Journal of the National Cancer Institute.

[Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment].

C. Ingvar, C. Rose, H. Jernström, 2005, Lakartidningen.

Stage and pattern of metastases in patients with breast cancer.

C Kamby, K. Zedeler, C. Rose, 1987, European journal of cancer & clinical oncology.

Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients

C. Ingvar, C. Rose, H. Jernström, 2011, British Journal of Cancer.

Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?

C. Rose, P. Pfeiffer, P. Sørensen, 1995, European journal of cancer.

Prognostic Usefulness of Estrogen Receptor Iimminocvtocheniical Assays for Human Breast Cancer 1

B. Rasmussen, C. Rose, K. Andersen, 2006 .

Prognostic Factors in Primary Breast Cancer: Second Thoughts

C. Rose, S. Thorpe, 1992 .

Metastatic pattern and response to endocrine therapy in human breast cancer

C. Rose, C. Kamby, 2005, Breast Cancer Research and Treatment.

Antiestrogen treatment of postmenopausal women with primary high risk breast cancer

H. Mouridsen, C. Rose, K. Andersen, 1983, Breast Cancer Research and Treatment.

Pattern of metastases in human breast carcinoma in relation to estrogen receptor status.

C. Rose, K. Andersen, N. Holm, 1986, Anticancer research.

Therapeutic effect of tamoxifen related to estrogen receptor level.

H. Mouridsen, C. Rose, T. Palshof, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.

M. Ro̸rth, H. Mouridsen, P. Dombernowsky, 1980, European journal of cancer.

Body size and menopausal status in relation to the pattern of spread in recurrent breast cancer.

K. Zedeler, C. Rose, J. Andersen, 1989, Acta oncologica.

The pattern of metastases in human breast cancer. Influence of systemic adjuvant therapy and impact on survival.

C Kamby, K. Zedeler, C. Rose, 1988, Acta oncologica.

Patients satisfaction with outpatient oncology consultations using the distress thermometer: comparison of two cohorts (2007 and 2012)

E. Beale, C. Rose, F. Rahemtulla, 2013 .

Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis.

C. Rose, S. Bentzen, K. Andersen, 1998, British Journal of Cancer.

Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women

C. Ingvar, C. Rose, H. Jernström, 2007, British Journal of Cancer.

Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer

O. Chinot, I. Christensen, I. Balslev, 1995 .

Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort

C. Ingvar, C. Rose, Andrea Markkula, 2012, Cancer Prevention Research.

Influence of systemic adjuvant therapy and impact on survival

K. Zedeler, C. Rose, J. Andersen, 1988 .

Quality control of estrogen and progesterone receptor analyses in Denmark.

C. Rose, H. Poulsen, S. Thorpe, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

The importance of surgery and accurate axillary staging for survival in breast cancer.

B. Carstensen, C. Rose, M. Jensen, 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Repeated fine needle aspirations in the diagnosis of soft tissue metastases in breast cancer.

I. Balslev, C. Rose, L. Pedersen, 1988, European Journal of Cancer and Clinical Oncology.

Fluosol DA and oxygen as an adjuvant to the radiotherapeutic management of advanced head/neck carcinoma.

C. Rose, R. Lustig, N. McIntosh-Lowe, 1988, Biomaterials, artificial cells, and artificial organs.

[Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial].

H. Mouridsen, P. Dombernowsky, C. Rose, 1991, Ugeskrift for læger.

Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort

C. Ingvar, C. Rose, A. Ringberg, 2012, Cancer Causes & Control.

A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study

F. Hirsch, H. Mouridsen, M. Andersson, 1998 .

Treatment of advanced breast cancer with progestins.

H. Mouridsen, C. Rose, M. Salimtschik, 1981, Acta obstetricia et gynecologica Scandinavica. Supplement.